RATIONALE: Extracellular-signal regulated protein kinase (ERK1/2) is activated by ethanol in reward-related brain regions. Accordingly, systemic inhibition of ERK1/2 potentiates ethanol reinforcement. However, the brain region(s) that mediate this effect are unknown. OBJECTIVE: This study aims to pharmacologically inhibit ERK1/2 in the medial prefrontal cortex (PFC), nucleus accumbens (NAC), and amygdala (AMY) prior to ethanol or sucrose self-administration, and evaluate effects of operant ethanol self-administration on ERK1/2 phosphorylation (pERK1/2). METHODS: Male C57BL/6J mice were trained to lever press on a fixed-ratio-4 schedule of 9% ethanol + 2% sucrose (ethanol) or 2% sucrose (sucrose) reinforcement. Mice were sacrificed immediately after the 30th self-administration session and pERK1/2 immunoreactivity was quantified in targeted brain regions. Additional groups of mice were injected with SL 327 (0-1.7 μg/side) in PFC, NAC, or AMY prior to self-administration. RESULTS: pERK1/2 immunoreactivity was significantly increased by operant ethanol (g/kg = 1.21 g/kg; BAC = 54.9 mg/dl) in the PFC, NAC (core and shell), and AMY (central nucleus) as compared to sucrose. Microinjection of SL 327 (1.7 μg) into the PFC selectively increased ethanol self-administration. Intra-NAC injection of SL 327 had no effect on ethanol- but suppressed sucrose-reinforced responding. Intra-AMY microinjection of SL 327 had no effect on either ethanol- or sucrose-reinforced responding. Locomotor activity was unaffected under all conditions. CONCLUSIONS: Operant ethanol self-administration increases pERK1/2 activation in the PFC, NAC, and AMY. However, ERK1/2 activity only in the PFC mechanistically regulates ethanol self-administration. These data suggest that ethanol-induced activation of ERK1/2 in the PFC is a critical pharmacological effect that mediates the reinforcing properties of the drug.
RATIONALE: Extracellular-signal regulated protein kinase (ERK1/2) is activated by ethanol in reward-related brain regions. Accordingly, systemic inhibition of ERK1/2 potentiates ethanol reinforcement. However, the brain region(s) that mediate this effect are unknown. OBJECTIVE: This study aims to pharmacologically inhibit ERK1/2 in the medial prefrontal cortex (PFC), nucleus accumbens (NAC), and amygdala (AMY) prior to ethanol or sucrose self-administration, and evaluate effects of operant ethanol self-administration on ERK1/2 phosphorylation (pERK1/2). METHODS: Male C57BL/6J mice were trained to lever press on a fixed-ratio-4 schedule of 9% ethanol + 2% sucrose (ethanol) or 2% sucrose (sucrose) reinforcement. Mice were sacrificed immediately after the 30th self-administration session and pERK1/2 immunoreactivity was quantified in targeted brain regions. Additional groups of mice were injected with SL 327 (0-1.7 μg/side) in PFC, NAC, or AMY prior to self-administration. RESULTS: pERK1/2 immunoreactivity was significantly increased by operant ethanol (g/kg = 1.21 g/kg; BAC = 54.9 mg/dl) in the PFC, NAC (core and shell), and AMY (central nucleus) as compared to sucrose. Microinjection of SL 327 (1.7 μg) into the PFC selectively increased ethanol self-administration. Intra-NAC injection of SL 327 had no effect on ethanol- but suppressed sucrose-reinforced responding. Intra-AMY microinjection of SL 327 had no effect on either ethanol- or sucrose-reinforced responding. Locomotor activity was unaffected under all conditions. CONCLUSIONS: Operant ethanol self-administration increases pERK1/2 activation in the PFC, NAC, and AMY. However, ERK1/2 activity only in the PFC mechanistically regulates ethanol self-administration. These data suggest that ethanol-induced activation of ERK1/2 in the PFC is a critical pharmacological effect that mediates the reinforcing properties of the drug.
Authors: Karen K Szumlinski; Mahdi E Diab; Raquel Friedman; Liezl M Henze; Kevin D Lominac; M Scott Bowers Journal: Psychopharmacology (Berl) Date: 2007-01-16 Impact factor: 4.530
Authors: S P Goulding; I Obara; K D Lominac; A T Gould; B W Miller; M Klugmann; K K Szumlinski Journal: Genes Brain Behav Date: 2010-10-18 Impact factor: 3.449
Authors: Jason P Schroeder; Marina Spanos; Jennie R Stevenson; Joyce Besheer; Michael Salling; Clyde W Hodge Journal: Neuropharmacology Date: 2008-07-04 Impact factor: 5.250
Authors: R Renteria; Z M Jeanes; R A Mangieri; E Y Maier; D M Kircher; T R Buske; R A Morrisett Journal: Int Rev Neurobiol Date: 2016-03-24 Impact factor: 3.230
Authors: Eric A Engleman; Cynthia M Ingraham; Zachary A Rodd; James M Murphy; William J McBride; Zheng-Ming Ding Journal: Drug Alcohol Depend Date: 2020-07-02 Impact factor: 4.492
Authors: Sara Faccidomo; Katarina S Swaim; Briana L Saunders; Taruni S Santanam; Seth M Taylor; Michelle Kim; Grant T Reid; Vallari R Eastman; Clyde W Hodge Journal: Psychopharmacology (Berl) Date: 2018-03-03 Impact factor: 4.530
Authors: Jessica L Hoffman; Sara Faccidomo; Michelle Kim; Seth M Taylor; Abigail E Agoglia; Ashley M May; Evan N Smith; L C Wong; Clyde W Hodge Journal: Int Rev Neurobiol Date: 2019-10-23 Impact factor: 3.230
Authors: Rebekah A Stevenson; Jessica L Hoffman; Antoniette M Maldonado-Devincci; Sara Faccidomo; Clyde W Hodge Journal: Behav Brain Res Date: 2019-03-23 Impact factor: 3.332
Authors: Sara Faccidomo; Grant T Reid; Abigail E Agoglia; Sherifat A Ademola; Clyde W Hodge Journal: Behav Brain Res Date: 2015-11-19 Impact factor: 3.332
Authors: Michael C Salling; Christopher J Hodge; Kelly E Psilos; Vallari R Eastman; Sara P Faccidomo; Clyde W Hodge Journal: Pharmacol Biochem Behav Date: 2017-10-31 Impact factor: 3.533
Authors: Jessica L Hoffman; Sara Faccidomo; Briana L Saunders; Seth M Taylor; Michelle Kim; Clyde W Hodge Journal: Alcohol Clin Exp Res Date: 2021-06-22 Impact factor: 3.455